MA28691B1 - Procede de traitement du cancer - Google Patents

Procede de traitement du cancer

Info

Publication number
MA28691B1
MA28691B1 MA29575A MA29575A MA28691B1 MA 28691 B1 MA28691 B1 MA 28691B1 MA 29575 A MA29575 A MA 29575A MA 29575 A MA29575 A MA 29575A MA 28691 B1 MA28691 B1 MA 28691B1
Authority
MA
Morocco
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
MA29575A
Other languages
English (en)
Inventor
Mark S Berger
Iman El-Hariry
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
David Rusnak
Neil L Spector
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA28691B1 publication Critical patent/MA28691B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA29575A 2004-06-03 2006-12-28 Procede de traitement du cancer MA28691B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57682504P 2004-06-03 2004-06-03
US60679004P 2004-09-02 2004-09-02

Publications (1)

Publication Number Publication Date
MA28691B1 true MA28691B1 (fr) 2007-06-01

Family

ID=35503647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29575A MA28691B1 (fr) 2004-06-03 2006-12-28 Procede de traitement du cancer

Country Status (14)

Country Link
US (1) US20100063074A1 (fr)
EP (1) EP1768963A4 (fr)
JP (1) JP2008501690A (fr)
KR (1) KR20070030240A (fr)
AU (1) AU2005251722B2 (fr)
BR (1) BRPI0511754A (fr)
CA (1) CA2569132A1 (fr)
IL (1) IL179359A0 (fr)
MA (1) MA28691B1 (fr)
MX (1) MXPA06013635A (fr)
NO (1) NO20066077L (fr)
NZ (1) NZ551622A (fr)
RU (1) RU2006142420A (fr)
WO (1) WO2005120504A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
EP2158913A1 (fr) * 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (fr) 2008-08-25 2010-03-03 Ratiopharm GmbH Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
PT2827900T (pt) 2012-03-23 2018-06-14 Array Biopharma Inc Dispersões sólidas amorfas para utilização no tratamento de cancro cerebral
WO2018201016A1 (fr) 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Traitement des cancers positifs à her2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CZ299561B6 (cs) * 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
WO2002056912A2 (fr) * 2001-01-16 2002-07-25 Glaxo Group Limited Methode de traitement du cancer
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
EP1496909B1 (fr) * 2002-04-16 2007-02-14 AstraZeneca AB Therapie combinee de traitement du cancer
EP1810034A4 (fr) * 2002-06-19 2008-06-25 Smithkline Beecham Corp Marqueurs predictifs utilises dans le traitement du cancer
WO2004013093A2 (fr) * 2002-08-02 2004-02-12 Immunogen, Inc. Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci
JP2004144680A (ja) * 2002-10-25 2004-05-20 Nanko Kyo 細胞増殖を制御する物質のスクリーニング方法、及びＳｐ１分子等をヌクレオリン（ｎｕｃｌｅｏｌｉｎ）分子から解離させる物質のスクリーニング方法

Also Published As

Publication number Publication date
WO2005120504A3 (fr) 2006-02-23
EP1768963A2 (fr) 2007-04-04
AU2005251722A1 (en) 2005-12-22
AU2005251722B2 (en) 2009-11-12
KR20070030240A (ko) 2007-03-15
US20100063074A1 (en) 2010-03-11
IL179359A0 (en) 2007-03-08
NO20066077L (no) 2007-01-31
JP2008501690A (ja) 2008-01-24
MXPA06013635A (es) 2007-02-28
BRPI0511754A (pt) 2008-01-02
RU2006142420A (ru) 2008-07-20
CA2569132A1 (fr) 2005-12-22
WO2005120504A2 (fr) 2005-12-22
NZ551622A (en) 2010-01-29
EP1768963A4 (fr) 2009-06-10

Similar Documents

Publication Publication Date Title
MA28901B1 (fr) Methode de traitement de cancers
DE602005012489D1 (de) Verfahren zur Abwasserbehandlung
IL185581A0 (en) Method of treating actinic keratosis
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
BRPI0810206A2 (pt) Método de tratar câncer
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005016127D1 (de) Substituierte hydantoine zur krebsbehandlung
FR2876047B1 (fr) Traitement de polluants par phytolixiviation
MA28691B1 (fr) Procede de traitement du cancer
FR2901405B1 (fr) Appareils de traitement
EP1833511A4 (fr) Methode de traitement du cancer du cerveau
FR2875236B1 (fr) Procede et installation pour le traitement de dso
FR2890981B1 (fr) Appareil et procede de traitement de cementation
BRPI0615165A2 (pt) método de tratamento de infertilidade
HK1139334A1 (en) Method of treating demyelination diseases
EP1988060A4 (fr) Procede de traitement d'eau usagee
ITMI20051107A1 (it) Metodo per il trattamento del cancro
FI20070455A0 (fi) Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
BR112012003653A2 (pt) "método de tratar o câncer."
IS8357A (is) Aðferð við að meðhöndla krabbamein með HDAC hindrum
FR2915390B1 (fr) Procede de traitement de la propolis
FR2908965B1 (fr) Ensemble cosmetique et procede de traitement cosmetique
FI20050633A (fi) Menetelmä ja laitteisto malmin käsittelyyn
FR2874154B1 (fr) Procede de decontamination de grains
FR2904622B1 (fr) Procede de traitement de lixiviat.